Samsung Bioepis Partners with NIPRO to Commercialize Biosimilars in Japan
Samsung Bioepis Co., Ltd., on June 8th, announced that the company has entered into a license, development and commercialisation agreement with NIPRO Corporation for multiple biosimilar candidates, including SB17, an ustekinumab biosimilar candidate, in Japan. Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, […]
